Anti-HCV Next
ABBOTT LABORATORIES · Decision date Sep 23, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 09/23/2026 for the 510(k) K262156, submitted by Abbott Laboratories for a device named Anti-HCV Next. The application was received 06/26/2026 and reviewed under regulation 866.3169, product code MZO, in the Microbiology specialty and review panel. The public record lists the device classification as Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus, and describes the submission as a traditional 510(k) not reviewed by a third party.
SESE denotes 510(k) clearance rather than premarket approval. The record states no combination product and no authorized predetermined change control plan, and it does not identify a specific modified component or describe performance data, so the technical basis for the clearance and any labeling remain unknown from this page.
The page was last updated 10/26/2026. No decision summary content, indications, or analytical performance information appears in the available text.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Sep 23, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262156
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- ABBOTT LABORATORIES
- Product code
- MZO
- Decision code
- SESE
- Decision date
- Sep 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus.
- Applicant
- ABBOTT LABORATORIES
- Product code
- MZO
- FDA device class
- 2
FDA decision timeline
K262156 received
Application receipt date recorded by FDA.
K262156 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ABBOTT LABORATORIES
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Abbott Park, IL
Sources and methodology
- Original FDA record: K262156
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records